Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States)

Cancer Causes and Control

Volumn 14, Issue 2, 2003, Pages 195-201

  Newcomb, Polly A ^a,b   Trentham Dietz, Amy ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Endometrial neoplasms; Estrogen; Estrogen replacement therapy; Postmenopause; Progestin

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; CANCER REGISTRY; CANCER RISK; CONFERENCE PAPER; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; TELEPHONE; UNITED STATES;

ADULT; AGED; CASE-CONTROL STUDIES; DATA COLLECTION; DRUG COMBINATIONS; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROGESTINS; RISK FACTORS; WISCONSIN;

EID: 0038637708     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023066304473     Document Type: Conference Paper

References (24)

1. Pike MC, Peters RK, Cozen W, et al. (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110-1116.
2. Persson I, Adami HO, Bergkvist L, et al. (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Brit Med J 298: 147-151.
3. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G (1991) Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338: 274-277.
4. Weiderpass E, Adami HO, Baron JA, et al. (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131-1137.
5. Jick SS, Walker AM, Jick H (1993) Estrogens, progesterone, and endometrial cancer. Epidemiol 4: 20-24.
6. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obst Gynecol 85: 304-313.
7. The Writing Group for the PEPI Trial (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 275: 370-375.
8. Woodruff JD, Pickar JH (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am J Obstet Gynecol 170: 1213-1223.
9. Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461.
10. Newcomb PA, Egan KM, Titus-Ernstoff L, et al. (1999) Lactation in relation to postmenopausal breast cancer. Am J Epidemiol 150: 174-182.
11. Beresford SA, Coker AL (1989) Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol 130: 202-205.
12. Breslow NE, Day NE (1980) Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Scientific Publications (Lyon), 5-338.
13. Grady D, Ernster VL (1997) Hormone replacement therapy and endometrial cancer: are current regimens safe? J Natl Cancer Inst 89: 1088-1089.
14. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S (1990) Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 162: 148-154.
15. Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA (1996) Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7: 575-580.
16. Hirvonen E (1996) Progestins. Maturitas 23(Suppl 1): S13-S18.
17. Stanczyk FZ (1994) Stucture-function relationships, potency, and pharmacokinetcis of progestogens. In: Lobo R. ed. Treatment of Postmenopausal Women: Basic and Clinical Aspects, New York: Raven Press, pp. 69-80.
18. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-333.
19. Lane G, Siddle NC, Ryder TA, Pryse-Davies J, King RJ, Whitehead MI (1986) Is Provera the ideal progestogen for addition to postmenopausal estrogen therapy? Fertil Steril 45: 345-352.
20. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW (1980) Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Brit Med J 280: 822-824.
21. Key TJ, Pike MC (1988) The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Brit J Cancer 57: 205-212.
22. Greendale GA, James MK, Espeland MA, Barrett-Connor E (1997) Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators. Am J Epidemiol 146: 763-770.
23. Jain MG, Rohan TE, Howe GR (1999) Agreement of self-reported use of menopausal hormone replacement therapy with physician reports. Epidemiol 10: 260-263.
24. Goodman MT, Nomura AM, Wilkens LR, Kolonel LN (1990) Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol 131: 815-825.